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Abstract
Introduction: The role of lipocalin 2 (LCN2) in type 2 diabetes mellitus (T2DM) needs to be fully elucidated. Moreover, bone has been 
demonstrated to modulate glucose metabolism via LCN2. We thus performed this study to investigate the association of LCN2 with 
indexes of glucose metabolism in T2DM. The associations of LCN2 with bone metabolism were examined concurrently.
Material and methods: A total of 288 Chinese Han subjects entered in this study, including 146 patients with T2DM and 142 subjects with 
normal glucose tolerance. Insulin resistance was assessed by HOMA-IR, and b-cell function was assessed by HOMA-b. For patients with 
T2DM, bone turnover markers, type 1 N-terminal procollagen, and collagen type 1 cross-linked C-telopeptide were assayed, and bone 
mineral density (BMD) of the lumbar spine and femoral neck were measured. 
Results: Serum LCN2 levels in T2DM were higher than those in subjects with normal glucose tolerance (p = 0.005). Moreover, LCN2 
was positively associated with fasting serum insulin (r = 0.262, p = 0.001), HOMA-IR (r = 0.185, p = 0.026), and HOMA-b (r = 0.306, 
p < 0.001), respectively, and negatively associated with fasting plasma glucose (r = –0.218, p = 0.006). Additionally, femoral neck BMD 
(b = –0.176, p = 0.033), type 1 N-terminal procollagen (b = 0.181, p = 0.026), and collagen type 1 cross-linked C-telopeptide (b = –0.168, 
p = 0.037) were independent predictors for LCN2 in T2DM.
Conclusions: LCN2 was associated with indexes of glucose metabolism. Furthermore, BMD and bone turnover markers were independ-
ent predictors for LCN2 in T2DM. We speculate that LCN2 might play a role in the cross-talk between bone homeostasis and glucose 
homeostasis. (Endokrynol Pol 2018; 69 (3): 276–282)
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Streszczenie
Wstęp: Wyjaśnienie roli lipokaliny-2 (lipocalin 2; LCN2) w przebiegu cukrzycy typu 2 jest niezbędne, w szczególności, że zostało dowie-
dzione, iż kość moduluje metabolizm glukozy za pośrednictwem LCN2. Niniejsze badanie przeprowadzono, aby zbadać, w jaki sposób 
LCN2 jest powiązana ze wskaźnikami metabolizmu glukozy w przebiegu cukrzycy typu 2. Jednocześnie zbadano powiązania LCN2 
z metabolizmem kostnym.
Materiał i metody: W badaniu wzięło udział 288 Chińczyków Han, w tym 146 pacjentów z cukrzycą typu 2 i 142 pacjentów z prawidłową 
tolerancją glukozy. Insulinooporność oceniano za pomocą wskaźnika HOMA-IR, natomiast funkcję komórek beta trzustki za pomocą 
HOMA-b. W przypadku pacjentów z cukrzycą typu 2 oznaczano również markery obrotu kostnego, N-końcowy propeptyd prokolagenu 
typu I, C-końcowy usieciowany telopeptyd łańcucha alfa kolagenu typu I, gęstość mineralną kości (bone mineral density; BMD) odcinka 
lędźwiowego kręgosłupa i szyjki kości udowej. 
Wyniki: Stężenia LCN2 w surowicy krwi w przebiegu cukrzycy typu 2 były wyższe niż u osób z prawidłową tolerancją glukozy 
(p = 0,005). Ponadto, LCN2 była dodatnio skorelowana ze stężeniem insuliny w surowicy krwi na czczo (r = 0,262, p = 0,001), wskaźnikiem 
HOMA-IR (r = 0,185, p = 0,026) i HOMA-b (r = 0,306, p < 0,001), odpowiednio, oraz ujemnie skorelowana z osoczowym stężeniem glukozy 
na czczo (r = –0,218, p = 0,006). Dodatkowo, BMD szyjki kości udowej (b = –0,176, p = 0,033), N-końcowy propeptyd prokolagenu typu I 
(b = 0,181, p = 0,026) oraz C-końcowy usieciowany telopeptyd łańcucha alfa kolagenu typu I (b = –0,168, p = 0,037) były niezależnymi 
czynnikami predykcyjnymi dla LCN2 w przebiegu cukrzycy typu 2. 
Wnioski: Lipokalina-2 była powiązana ze wskaźnikami metabolizmu glukozy. Ponadto, BMD oraz markery obrotu kostnego były nie-
zależnymi czynnikami predykcyjnymi dla LCN2 w przebiegu cukrzycy typu 2. Można sądzić, że LCN2 może odgrywać rolę w procesie 
wzajemnego wpływu homeostazy kości i homeostazy glukozy. (Endokrynol Pol 2018; 69 (3): 276–282) 
Słowa kluczowe: lipokalina-2, cukrzyca typu 2, gęstość mineralna kości
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Introduction
Lipocalin 2 (LCN2), a protein also known as neutrophil 
gelatinase-associated lipocalin, 24p3, or siderocalin, 
belongs to the lipocalin superfamily [1]. LCN2 is abun-
dantly expressed in various tissues such as immune 
cells, adipose tissue, lung, liver, kidney, and uterus, and 
is implicated in diseases associated with inflammation 
and obesity including inflammatory bowel disease, 
cardiovascular disease, acute kidney injury, acute pan-
creatitis, cancer, multiple sclerosis, and type 2 diabetes 
mellitus (T2DM) [2–7].
Notably, LCN2 is also involved in bone metabolism. 
A study by Costa et al. indicated that osteoblasts in mice 
expressed LCN2. Moreover, their study suggested that 
LCN2 exerted both a negative effect on bone formation 
and a positive effect on bone resorption [8]. Another 
study supported the role of LCN2 in inducing bone loss 
[9]. Most recently, Mosialou et al. found that osteoblasts 
in mice expressed LCN2 at higher levels than white 
adipose tissue and other tissues. LCN2 derived from 
bone improved glucose tolerance and insulin sensitivity 
[10]. Their findings revealed the endocrine function of 
bone, which modulates glucose metabolism via LCN2. 
However, the relationship between bone and LCN2 in 
humans remains little known. 
In humans, clinical reports have described the re-
lationship between LCN2 and insulin resistance, β-cell 
function, and risk for T2DM in humans in recent de-
cades. Wang et al. reported that serum LCN2 levels were 
significantly elevated in obese subjects and positively 
correlated with the index of insulin resistance, homeo-
stasis model assessment for insulin resistance (HOMA-
IR), and fasting glucose [11]. A study of a large-scale Chi-
nese population indicated that serum LCN2 levels were 
higher in subjects with newly diagnosed T2DM than 
in subjects with normal glucose tolerance (NGT) and 
positively associated with fasting insulin and HOMA-IR 
in the whole population [12]. Moreover, elevated serum 
LCN2 level was shown to be associated with increased 
risk for T2DM. A recent study also indicated that LCN2 
levels were elevated in obese women and could be 
used as an early predictor of T2DM [13]. Nevertheless, 
no significant association of LCN2 with HOMA-IR 
was indicated in non-diabetic obese women [14]. 
In young healthy men, LCN2 was not shown to be 
associated with insulin resistance [15]. A study using 
euglycaemic hyperinsulinaemic clamp method in 
healthy middle-aged men showed no correlation be-
tween LCN2 and insulin sensitivity [16]. For patients 
with T2DM, Xiao et al. found that LCN2 had positive 
correlation with fasting insulin, but no correlation with 
fasting glucose or insulin resistance [17]. 
In addition to insulin resistance, impairment of 
β-cell function is one of the most important aetiological 
factors for the development and progression of T2DM. 
Remarkably, LCN2 was shown to be a biomarker for 
assessing severity of acute pancreatitis, which is one 
of the causes of impairment of β-cell function [5]. Con-
cerning insulin secretion, a weak negative correlation 
between LCN2 and β-cell function index, homeostatic 
model assessment for insulin secretion (HOMA-β), was 
displayed [18]. Nevertheless, few published studies 
have reported on the association of LCN2 with β-cell 
function in patients with T2DM.
Collectively, the published observations on the re-
lationship between LCN2 and indexes of insulin resist-
ance and insulin secretion are discrepant in humans. 
The role of LCN2 in glucose metabolism needs to be 
fully elucidated in patients with T2DM. We carried out 
the study herein to investigate the associations of LCN2 
with insulin resistance and insulin secretion in patients 
with T2DM. In addition, considering the latest finding 
that bone may modulate glucose metabolism via LCN2, 
the association between bone and serum LCN2 levels 
was examined concurrently. To our knowledge, this is 
first report on this issue in T2DM. 
Material and methods
A total of 288 participants entered in this study, in-
cluding 146 diabetic subjects and 142 NGT subjects 
matching the age, sex, and body mass index (BMI) 
with diabetic subjects. The ethnicity of all subjects 
was Han. The participants were recruited from either 
the Department of Endocrinology of Anhui Provincial 
Hospital in Hefei, China or the Sanlian community of 
the Shushan District and the Sanxiaokou community 
of the Luyang District in Hefei, China, from April 
2017 to October 2017. All participants undertook 75-g 
oral glucose tolerance test (OGTT), and blood at 0 h 
and 2 h was collected in order to assay fasting and 
postprandial plasma glucose as well as fasting insulin 
levels. T2DM and NGT were diagnosed according to 
the criteria of the World Health Organisation (WHO) 
1999. For those with T2DM, subjects fulfilling the fol-
lowing criteria were excluded from this study: (i) acute 
diabetic complications; (ii) on insulin treatment; (iii) 
using agents including thiazolidinediones, vitamin K, 
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warfarin, vitamin D, calcium supplement, bisphospho-
nates, vitamin A, and sex hormones; (iv) bone diseases 
such as bone tumours, osteoporosis, and fracture; 
(v) diabetic patients with albumin/creatinine ratio 
above 30 mg/g creatinine, liver disease, cardiovascular 
disease, kidney injury, lung disease, ovarian tumour, 
thyroid diseases, parathyroid diseases, and other endo-
crine diseases; (vi) infection, trauma, major operation, 
and other stress; (vii) type 1 diabetes mellitus, second-
ary diabetes mellitus, and gestational diabetes mellitus. 
This study was approved by the Ethics Committee of 
the First Affiliated Hospital of University of Science and 
Technology of China and was carried out in accordance 
with Declaration of Helsinki for experiments involving 
humans (approval number LLSC20160036 issued on 
6 December 2016). Written, informed consent had been 
obtained from all participants before their inclusion in 
this study.
The height and weight of the total subjects were 
measured by trained nurses. After overnight fasting 
for 10–12 h, venous blood was collected from all sub-
jects to assay total cholesterol (TC), triglyceride (TG), 
serum creatinine (sCr), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), alkaline phosphatase 
(ALP), fasting plasma glucose (FPG), fasting serum 
insulin (FIns), and glycosylated haemoglobin (HbA1c). 
For subjects who undertook OGTT, 2-h postprandial 
glucose (2hPG) was collected to assess postprandial 
plasma glucose. For subjects with T2DM, the serum 
bone turnover markers (BTMs), type 1 N-terminal 
procollagen (P1NP), and collagen type 1 cross-linked 
C-telopeptide (CTX) were assayed.
Serum insulin was assayed by electrochemilumi-
nescence immunoassay (Roche Diagnostics GmbH, 
Mannhein, Germany). HbA1C was assayed by high- 
-pressure liquid chromatography method (Bio-Rad Inc., 
Hercules, CA, USA). Serum LCN2 levels were measured 
by enzyme-linked immunosorbent assay (ELISA) kit 
(RayBiotech Human Lipocalin-2 ELISA kit, RayBiotech 
Inc., Norcross, GA, USA). P1NP and CTX were assayed 
by electrochemical luminescence immunoassay on an 
automated Elecsys 2010 analyser (Roche Diagnostics 
GmbH, Mannheim, Germany). Measurements of glu-
cose, TC, TG, sCr, ALT, AST, and ALP were performed by 
a Hitachi 7600 automatic biochemical analyser (Hitachi 
Ltd., Tokyo, Japan). 
Bone mineral density (BMD) was measured by dual-
energy X-ray absorptiometry (DXA) using a GE Lunar 
densitometer (Lunar, GE Healthcare, Madison, WI, 
USA) in patients with T2DM. The BMD of the lumbar 
spine (L1–L4) and femoral neck were measured, respec-
tively. The coefficients of variation of measurements 
of the lumbar spine and femoral neck were 1.2% and 
1.0%, respectively.
The BMI was calculated by dividing weight in 
kilograms (kg) by height in metres squared (m2). 
The HOMA-β was used to assess basal insulin secre-
tion, which was calculated as 20 × FIns (mU/L)/(FPG 
(mmol/L)–3.5). Insulin resistance was assessed by 
HOMA-IR, which was calculated as FIns (mU/L) × 
FPG (mmol/L)/22.5.
Statistical analyses
Data were examined for normal distribution by Kol-
mogorov-Smirnov test, and the skewed distributed 
data were log transformed to normality before further 
analysis. Data were expressed as mean ± standard 
deviation (SD). The differences in variables between 
two groups were assessed by unpaired two-tailed t-test 
except the ratio of male to female, which was analysed 
by Χ2 test. Pearson correlation analysis was used to 
examine the correlation between LCN2 and various 
indexes of glucose and bone metabolism. Multiple 
stepwise regression analysis was performed to assess 
multivariate correlations. All analyses were performed 
using the SPSS Statistical Package version 20.0 (SPSS 
Inc., Chicago, IL, USA). Statistical significance was 
considered as p < 0.05.
Results
The anthropometrical and biochemical parameters from 
both the T2DM group and the NGT group are shown 
in Table I. No significant differences in BMI, the ratio of 
male to female, age, sCr, AST, and ALP were observed 
between the T2DM group and the NGT group (all p > 
0.05), whereas TG, TC, and ALT were significantly dif-
ferent in the two groups (all p < 0.05). As expected, the 
T2DM group had higher FPG, 2hPG, FIns, HbA1c, and 
HOMA-IR and lower HOMA-β than the NGT group (all 
p < 0.05). Moreover, serum LCN2 levels were higher in 
the T2DM group compared to the NGT group (166.54 
± 45.31 vs. 122.53 ± 26.15, p = 0.005).
Next, all T2DM subjects were stratified into two 
groups according to serum LCN2 levels (Table II). The 
unpaired t-test showed that diabetic patients with 
low LCN2 levels were older and had lower sCr, FIns, 
HOMA-IR, HOMA-β, and P1NP compared to diabetic 
patients with high LCN2 levels (all P < 0.05). FPG, 
lumbar BMD, femoral neck BMD, and CTX were higher 
in the low-LCN2 group than in the high-LCN2 group 
(all P < 0.05). No significant differences were observed 
between the two groups in regard to the ratio of male 
to female, BMI, ALT, AST, ALP, TG, TC, and HbA1c, re-
spectively (all P > 0.05).
Subsequently, the correlations between the serum 
LCN2 levels and various indexes of glucose and bone 
metabolism were assessed. As shown in Table III, the 
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serum LCN2 levels positively correlated to FIns (r = 
0.270, p = 0.001), HOMA-IR (r = 0.185, p = 0.026), 
and HOMA-β (r = 0.316, p < 0.001), respectively, and 
negatively correlated to FPG (r = –0.228, p = 0.006). 
Negative correlation between serum LCN2 levels and 
lumbar BMD (r = –0.223, p = 0.007) as well as femoral 
neck BMD (r = –0.237, p = 0.004) was shown. Moreover, 
serum LCN2 levels positively correlated with P1NP 
(r = 0.213, p = 0.010) and negatively correlated with CTX 
(r = –0.194, p = 0.019). For the other indexes, no signifi-
cant correlations were observed (all p > 0.05). 
To further determine whether LCN2 and other pa-
rameters were independently associated with indexes 
of glucose metabolism, multivariate stepwise regres-
sion analysis was performed. Results showed that 
LCN2 was positively associated with FIns (b = 0.262, 
p = 0.001), HOMA-IR (β = 0.185, p = 0.026), and 
HOMA-b (b = 0.306, p < 0.001) , respectively, and 
negatively associated with FPG (β = –0.218, p = 0.006) 
independently of age, sex, BMI, and duration of T2DM, 
Table I. Comparison of clinical parameters between NGT 
group and T2DM group
Tabela I. Porównanie parametrów klinicznych osób z grupy 
z prawidłową tolerancją glukozy i osób z cukrzycą typu 2
Group NGT T2DM  p  
 (n = 142) (n = 146)  
Male/Female (n) 72/70 74/72 0.831#
Age (years) 56.82 ± 11.57 57.74 ± 11.06 0.104
BMI [kg/m2] 24.67 ± 3.13 24.55 ± 3.31 0.820
sCr [μmol/L] 63.18 ± 15.07 62.07 ± 16.35 0.379
ALT [U/L] 20.50 ± 10.75 24.29 ± 15.43* 0.017
AST [U/L] 22.01 ± 6.32 22.88 ± 9.69 0.332
ALP [U/L] 71.00 ± 29.64 72.48 ± 23.92 0.633
TG [mmol/L] 1.52 ± 0.94 2.11 ± 1.55* < 0.001
TC [mmol/L] 4.83 ± 0.75 4.46 ± 1.11* < 0.001
FPG [mmol/L]  5.16 ± 0.57 8.73 ± 2.36* < 0.001
2hPG [mmol/L] 7.11 ± 0.66 14.85 ± 4.78* < 0.001
Log10 FIns [mIU/L] 0.83 ± 0.13 0.89 ± 0.25  0.045
HbA1C (%) 5.35 ± 0.39 9.21 ± 2.15* < 0.001
Log10 HOMA-IR 0.20 ± 0.15 0.46 ± 0.21* < 0.001
Log10 HOMA-β 1.95 ± 0.26 1.53 ± 0.32* < 0.001 
LCN2 [ng/mL]  122.53 ± 26.15 166.54 ± 45.31* 0.005 
Normally distributed data are presented as mean ± SD. Skewed distributed data 
were log transformed to normality. 2hPG — 2-h postprandial glucose; ALT — alanine 
aminotransferase; AST — aspartate aminotransferase, ALP — alkaline phosphatase; 
BMI — body mass index; Fins — fasting serum insulin; FPG — fasting plasma 
glucose; HbA1c — glycosylated haemoglobin; HOMA-β — homeostatic model 
assessment for β-cell function; HOMA-IR — homeostasis model assessment for 
insulin resistance; LCN2 — lipocalin 2; NGT — normal glucose tolerance;  
sCr — serum creatinine; T2DM — type 2 diabetes mellitus; TC — total cholesterol; 
TG — triglycerides. #Chi-squared test. *P < 0.05 vs. NGT group
Table II. Comparison of clinical parameters of T2DM patients 
stratified by serum LCN2 levels below/equal or above median
Tabela II. Porównanie parametrów klinicznych osób z cukrzycą 
typu 2, podzielonych pod względem stężenia lipokaliny-2 
w surowicy krwi poniżej/równo lub powyżej średniej
Group LCN2  LCN2 
 < median  > median p 
 (n = 73)  (n = 73)  
Male/Female (n) 37/36 35/38 0.833#
Age (years) 62.17 ± 10.22 57.95 ± 10.39* 0.010
BMI [kg/m2] 24.08 ± 3.09 24.62 ± 3.03 0.892
sCr (μmol/L] 57.52 ± 14.71 65.84 ± 12.75* 0.002
ALT [U/L] 26.23 ± 16.54 22.34 ± 14.04 0.090
AST [U/L] 23.12 ± 10.44 22.65 ± 8.92 0.747
ALP [U/L] 75.18 ± 20.45 74.52 ± 16.56 0.890
TG [mmol/L] 1.91 ± 1.60 2.22 ± 1.29 0.124
TC [mmol/L] 4.45 ± 1.05 4.47 ± 1.10 0.905
FPG [mmol/L]  9.10 ± 2.44 8.29 ± 2.20* 0.037
Log10 FIns [mIU/L] 0.81 ± 0.25 0.98 ± 0.23* < 0.001
HbA1C (%) 9.11 ± 2.19 9.16 ± 2.13 0.808
Log10 HOMA-IR 0.40 ± 0.21 0.53 ± 0.22* 0.003
Log10 HOMA-β 1.41 ± 0.35 1.65 ± 0.38* < 0.001
P1NP [ng/mL] 33.58 ± 12.66 39.08 ± 16.75* 0.031
CTX [ng/mL] 459.12 ± 167.90 401.27 ± 182.06* 0.044
Femoral neck BMD  0.95 ± 0.13  0.87 ± 0.17* 0.004 
[g/cm2]
Lumbar BMD [g/cm2]  1.17 ± 0.19 1.07 ± 0.19* 0.003
BMD — bone mineral density; CTX — collagen type 1 cross-linked 
C-telopeptide; P1NP — type 1 N-terminal procollagen
#Chi-squared test, *p < 0.05 vs. low LCN2 group
Table III. Correlation analysis between LCN2 and various 
indexes of glucose and bone metabolism in T2DM
Tabela III. Analiza korelacji między lipokaliną-2 i różnymi 
wskaźnikami metabolizmu glukozy i metabolizmu kostnego 
w cukrzycy typu 2
 r p
FPG –0.228 0.006
Log10 FIns 0.270 0.001
HbA1c –0.041 0.621
Log10 HOMA-IR 0.185 0.026
Log10 HOMA-β 0.316 < 0.001
ALP –0.013 0.875
P1NP 0.213 0.010
CTX –0.194 0.019
Femoral neck BMD –0.237 0.004
Lumbar BMD –0.223 0.007
Pearson correlation analysis was used. r — Pearson correlation coefficient
P < 0.05 (significant difference)
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TG, TC, ALP, P1NP, CTX, femoral neck BMD, and lum-
bar BMD (Table IV).
Because a recent study in an animal model revealed 
that bone-derived LCN2 is implicated in glucose me-
tabolism, the relationship between LCN2 and bone 
was examined [10]. The multiple stepwise regression 
analysis showed that femoral neck BMD (β = –0.176, 
p = 0.033), P1NP (β = 0.181, p = 0.026), and CTX 
(β = –0.168, p = 0.037) were independent predictors of 
LCN2 in T2DM (Table V). The lumbar BMD and ALP 
were not significantly associated with serum LCN2 
levels (both p > 0.05). 
Discussion
In this study, serum LCN2 levels were shown to be high-
er in the T2DM group than in the NGT group, consistent 
with previous reports [12, 19]. Since BMI and sex have 
been shown to be related to serum LCN2 levels in hu-
man, the subjects in the NGT group who had no statisti-
cal differences in those parameters compared to T2DM 
group were chosen as controls in this study [14, 20]. 
A number of factors correlating to serum LCN2 levels 
have been identified in the past decade, including 
lung injury, kidney injury, pancreatic injury, and car-
diovascular disease [3, 5, 21, 22]. Moreover, diabetic 
complications such as diabetic retinopathy and diabetic 
kidney disease have been demonstrated to be positively 
correlated to serum or urinary LCN2 levels [23, 24]. Ad-
ditionally, serum and urinary LCN2 levels have been 
reported to be linked to the risk of cardiovascular dis-
ease in T2DM [25]. Therefore, subjects included in this 
study had none of the diseases or diabetic complications 
mentioned above.
The serum LCN2 levels were higher in T2DM than 
in NGT and negatively associated with FPG, suggesting 
a potential role in T2DM. This study showed that serum 
LCN2 levels were positively associated with FIns, as 
well as HOMA-β, the index assessing basal β-cell func-
tion, suggesting that LCN2 may contribute to insulin 
secretion in T2DM. These data are in agreement with 
the findings in transgenic mice [10]. In these transgenic 
mice lacking LCN2 in osteoblasts, insulin secretion was 
shown to be reduced in response to glucose or arginine 
challenge while islet number and size, β-cell mass, 
and β-cell proliferation decreased in the pancreas. It is 
noteworthy that a study by Zhang et al. showed that 
insulin stimulated LCN2 expression and secretion in 
a glucose-dependent manner [26]. Thus, further stud-
ies are required to elucidate the casual relationship 
between LCN2 and insulin secretion. 
Comparable to the reports in subjects with IGR 
and newly diagnosed T2DM, we observed a positive 
association of LCN2 with HOMA-IR, the index of 
insulin resistance, in patients with T2DM [12]. Given 
that the diabetic study population in this study were 
a combination of long disease duration and short dis-
ease duration patients, this result suggests that LCN2 
might be involved in the whole pathological processes 
of T2DM. The association of LCN2 with insulin re-
sistance is supported by the in vitro study in which 
knockdown of LCN2 in cultured adipocytes improved 
insulin action and glucose uptake in H4IIe hepatocytes 
[27]. Moreover, recent studies on pro-inflammatory 
cytokines, such as interleukin-1β, interferon-γ, and 
TNF-α, which are closely linked to insulin resistance, 
coincidently up-regulated LCN-2 expression and secre-
tion [23, 28–30]. Nitric oxide (NO), commonly involved in 
inflammatory processes, also affected LCN2 protein sta-
bility [31]. Conversely, LCN2 has been demonstrated to 
antagonise the detrimental effects of inflammatory mol-
ecules on inflammation and metabolism in adipocytes 
Table V. Multiple stepwise regression analysis for the 
independent predictors of LCN2 in T2DM
Tabela V. Analiza regresji wielokrotnej krokowej dla 
niezależnych czynników predykcyjnych lipokaliny-2 
w cukrzycy typu 2
Predictors  β (95% CI)  p 
femoral neck BMD –0.176 0.033
P1NP 0.181 0.026
CTX –0.168 0.037
Skewed distributed data were log transformed to normality before analysis. 
Alkaline phosphatase (ALP), collagen type 1 cross-linked C-telopeptide (CTX), 
type 1 N-terminal procollagen (P1NP), femoral neck BMD (bone mineral density), 
and lumbar BMD served as independent variables
Table IV. Multiple stepwise regression analysis for indexes 
of glucose metabolism in T2DM
Tabela IV. Analiza regresji wielokrotnej krokowej dla 
wskaźników metabolizmu glukozy w cukrzycy typu 2
Dependent variables Predictors  β (95% CI)  p 
FPG LCN2 –0.218 0.006
 HbA1c 0.244 0.002
Log10 FIns LCN2 0.262 0.001
 HbA1c –0.212 0.008
Log10 HOMA-IR LCN2 0.185 0.026
Log10 HOMA-β LCN2 0.306 < 0.001
 HbA1c –0.243 0.002
Skewed distributed data were log transformed to normality before analysis. Age, 
body mass index (BMI), duration of diabetes, sex, glycosylated haemoglobin 
(HbA1c), lipocalin 2 (LCN2), total cholesterol (TC), triglycerides (TG), alkaline 
phosphatase (ALP), collagen type 1 cross-linked C-telopeptide (CTX), type 1 
N-terminal procollagen (P1NP), femoral neck BMD (bone mineral density), and 
lumbar BMD served as independent variables
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and macrophages [32]. Furthermore, data from patients 
with T2DM confirmed the positive correlation of serum 
LCN2 with inflammatory markers, including CRP, IL-6, 
and TNF-α [11, 12, 33–35]. However, although preclini-
cal and clinical studies suggest a positive association of 
LCN2 with insulin resistance, some contradictory data 
exist. On the whole, more studies in large-scale popula-
tions are required to clarify the relationship between 
LCN2 and insulin resistance.
Emerging evidence has revealed the association 
of LCN2 with bone. Costa et al. found that transgenic 
mice over-expressing LCN2 in bone displayed bone 
micro-architectural changes and reduced bone mass, 
including a thinner layer of cortical bone and a de-
creased trabecular number [8]. LCN2 was also shown 
to reduce osteoblast differentiation and be involved in 
osteoblast-osteoclast coupling [8, 9]. The latest study 
demonstrates that bone is the main source of LCN2 in 
mice [10]. In agreement to the findings in the animal 
models mentioned above, this study is the first report 
showing that serum LCN2 levels correlate to both 
BMD and BTMs in patients with T2DM. Furthermore, 
femoral neck BMD, P1NP, and CTX were found to be 
independent predictors of LCN2 in T2DM.
As noted in a recent meta-analysis, patients with 
T2DM had a greater risk of fracture compared with 
that in non-diabetic subjects, although the underlying 
mechanisms remain unclear [36]. Growing evidence 
has demonstrated that hyperglycaemia has harmful 
effects on bone microarchitecture and bone strength 
in T2DM, whereas high insulin levels contribute to 
bone formation [37–40]. Since bone remodelling oc-
curs continuously in the body, and requires energy 
consumption, good glycaemic control is beneficial to 
maintain bone homeostasis in T2DM. In this study, the 
negative association of LCN2 with FPG and positive 
association with insulin secretion suggest its role in 
anti-hyperglycaemia in T2DM. Of note, a recent study 
indicated that bone is the main source of circulating 
LCN2, and osteoblasts expressed higher levels of LCN2 
compared to white adipose tissue and other tissues [10]. 
Therefore, we propose a feedback regulation loop in 
the cross-talk between bone homeostasis and glucose 
homeostasis via LCN2. Hyperglycaemia inhibits bone 
metabolism, reduces bone mass and strength, stimulates 
the expression and secretion of bone-derived LCN2 into 
circulation. Elevated serum LCN2 levels promote the 
secretion of insulin, thereafter decreasing blood glucose, 
which contributes to improved bone metabolism.
Conclusions
In this study, we found serum LCN2 levels were 
higher in T2DM than in NGT. Serum LCN2 levels were 
negatively associated with FPG and positively associ-
ated with the indexes of insulin secretion and insulin 
resistance in T2DM. Serum LCN2 levels correlated to 
both BMD and BTMs in patients with T2DM. Further-
more, femoral neck BMD and BTMs, P1NP, and CTX 
were independent predictors of serum LCN2 levels in 
T2DM. We hereby speculate that LCN2 plays a role in 
the cross-talk between bone and glucose homeostasis. 
However, because it was a cross-sectional study, we 
could not identify the casual relationship between 
LCN2 and glucose metabolism or bone metabolism. 
Large-scale prospective studies are required to address 
this issue. Another limitation is that some of the patients 
in this study had received several treatments. Thus, we 
could not completely exclude the interference of these 
drugs when interpreting the associations of LCN2 with 
indexes of glucose and bone metabolism.
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